MEGGLE launching new InhaLac® 240 sieved DPI lactose at DDL Edinburgh

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will again use the Drug Delivery to the Lungs (DDL) Conference in Edinburgh, Scotland, as a launchpad for its latest expansion to its extensive range of lactose-based dry powder inhalation (DPI) excipients.

MEGGLE will introduce its new DPI sieved lactose product as a prominent presence at the conference as a Gold Sponsor and exhibitor at the Edinburgh International Conference Centre.

MEGGLE has a long-standing relationship with the DDL conference, having been a consistent supporter and sponsor for several years.

Closing the gap

InhaLac® 240 will be a centerpiece of the MEGGLE stand display of its sieved, milled and micronized DPI grade excipients from Booth 187 in the DDL Exhibition Zone.

This latest InhaLac® grade is engineered as a lactose monohydrate for inhalation with distinct PSD characterized by median particle size of 65 μm and a fines content of less than 5% below 10 μm. This makes the new grade more homogenous than the coarser InhaLac® 230 but also makes it slightly more free-flowing than the next grade up, InhaLac® 251.

These attributes provide an excellent platform for further customization by manufacturers.

About MEGGLE

Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.

MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose^®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose^® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About DDL 2024

The Drug Delivery to the Lungs (DDL) Conference (DDL) has become one of the leading international Pulmonary and Nasal Drug Delivery Conferences, providing an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation.

The 35th anniversary meeting, DDL 2024, is a three-day event opening December 11, again at the Edinburgh International Conference Center at The Exchange, close to University of Edinburgh.

The 2024 conference will feature five themed sessions each with a combination of invited and submitted lectures given by experts in the field of inhalation and students working to advance respiratory science. Major themes will include the Transition to New Propellants, Advances in Nasal Drug Delivery, and Current Innovations in Developing Inhalation Technology.

The event is organized by The Aerosol Society, with more information at: https://ddl-conference.com/

Resources

Click on Sieved lactose for dry powder inhalation to learn more.
Click on InhaLac Technical Brochure to download pdf brochure.